



Product Details

| Product name: | Anti-human CD19 (tafasitamab Biosimilar) | SKU: | BIO0002SM |
|-----------------|---|--------------------|-----------------|
| Target Name: | CD19 | Size: | 1 mg/5 mg/20 mg |
| Target Uniprot: | P15391 | Concentration: | Lyophilized |
| Clone#: | tafasitamab | Isotype: | Human IgG1 |
| Reactivity: | Human, Cynomolgus, Rhesus | Calculated M.W.: | 147.42 kDa |
| Application: | ELISA, Bioactivity: FACS, Functional assay, Research in vivo | Endotoxin: | <0.001 EU/ug |
| Formulation: | 0.1M Pro, 20mM Arg, pH5.0 | Conjugation: | None |
| Storage: | For long term storage, the produce should be stored at -20° C or lower. | Expression System: | СНО |
| Reconstitution: | Dissolve with sterile ddH2O | Purification: | Protein A |


Data

Purity:SDS-PAGE




Anti-CD19 (tafasitamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Bioactivity:ELISA




Immobilized human CD19 (20 291) Protein, His Tag at 2 ug/mL can bind Anti-CD19 (tafasitamab), EC50=0.0904 ug/mL.

Purity:SEC-HPLC



The purity of Anti-CD19 (tafasitamab) is 98.59%, determined by SEC-HPLC.

Bioactivity:FACS



Human CD19 HEK293 cells were stained with Anti-CD19 (tafasitamab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.085 ug/mL.